attached
Awaiting price reaction for this filing.
MPS Pharmaa Limited (formerly Advik Laboratories) has filed its half-yearly disclosure of related party transactions with BSE as required under SEBI LODR Regulation 23(9). Key transactions disclosed include: an unsecured loan of Rs. 41.21 lacs outstanding from Mr. Peeyush Kumar Aggarwal (Managing Director and Promoter Group member); an unsecured loan of Rs. 663.78 lacs from Omkam Global Capital Private Limited (a Common Director-related entity); remuneration paid to CFO Mr. Manoj Bhatia and Company Secretary Ms. Pooja Chuni; and an advance of Rs. 60,000 given to the CFO against salary for a medical emergency. The filing is signed by the Company Secretary and submitted to both BSE and Ahmedabad Stock Exchange.
This is a routine regulatory disclosure, not a new event, so it is unlikely to move the stock price. However, investors should note the material unsecured loan from a related entity (Omkam Global Capital) and the continued reliance on promoter-group funding, which signals ongoing capital support from insiders but also highlights related-party exposure. The name change from Advik Laboratories to MPS Pharmaa is also noted on the letterhead.